Cassiopea Announces Top Line Positive Proof of Concept Phase II Results for CB-06-02 Immune Modulator in Treating Genital Warts
Cassiopea SpA, a clinical-stage pharmaceutical company developing and commercializing innovative medical dermatology products, today announced that the proof of concept phase II clinical trial for its CB-06-02 topical 15% immune modulator tellurium-based gel for the treatment of external genital warts in women demonstrated statistically significant successful complete clearance rates in the PP population and successful complete clearance rates in the ITT population.